Shell Asset Management Co. lessened its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) by 15.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,649 shares of the biopharmaceutical company’s stock after selling 2,751 shares during the quarter. Shell Asset Management Co.’s holdings in Xenon Pharmaceuticals were worth $578,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Advisory Research Inc. lifted its stake in Xenon Pharmaceuticals by 4.1% during the third quarter. Advisory Research Inc. now owns 36,438 shares of the biopharmaceutical company’s stock worth $1,316,000 after purchasing an additional 1,438 shares during the last quarter. DNB Asset Management AS purchased a new stake in shares of Xenon Pharmaceuticals in the 4th quarter worth about $3,728,000. SG Americas Securities LLC boosted its position in Xenon Pharmaceuticals by 62.4% during the 4th quarter. SG Americas Securities LLC now owns 35,465 shares of the biopharmaceutical company’s stock valued at $1,398,000 after acquiring an additional 13,633 shares in the last quarter. International Biotechnology Trust PLC grew its stake in Xenon Pharmaceuticals by 3,194.6% in the third quarter. International Biotechnology Trust PLC now owns 25,500 shares of the biopharmaceutical company’s stock worth $918,000 after purchasing an additional 24,726 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of Xenon Pharmaceuticals by 41.2% in the 3rd quarter. Marshall Wace LLP now owns 2,811,095 shares of the biopharmaceutical company’s stock worth $101,480,000 after acquiring an additional 820,723 shares in the last quarter. Hedge funds and other institutional investors own 92.49% of the company’s stock.
Insider Transactions at Xenon Pharmaceuticals
In related news, Director Simon N. Pimstone sold 19,232 shares of the firm’s stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $36.98, for a total value of $711,199.36. Following the completion of the transaction, the director now directly owns 34,002 shares of the company’s stock, valued at $1,257,393.96. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 6.06% of the company’s stock.
Xenon Pharmaceuticals Stock Performance
Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) last issued its earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.01. Xenon Pharmaceuticals had a negative return on equity of 17.90% and a negative net margin of 862.06%. The firm’s revenue was down 100.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.57) EPS. Research analysts expect that Xenon Pharmaceuticals Inc. will post -2.77 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages recently issued reports on XENE. StockNews.com initiated coverage on shares of Xenon Pharmaceuticals in a research note on Thursday, March 16th. They issued a “sell” rating on the stock. Needham & Company LLC restated a “buy” rating and issued a $50.00 price target on shares of Xenon Pharmaceuticals in a research note on Friday, April 21st. JPMorgan Chase & Co. reissued a “top pick” rating on shares of Xenon Pharmaceuticals in a research report on Tuesday, April 25th. Royal Bank of Canada reiterated an “outperform” rating and issued a $51.00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday, March 22nd. Finally, Cantor Fitzgerald began coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, April 25th. They set an “overweight” rating and a $58.00 target price for the company. One research analyst has rated the stock with a sell rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $51.36.
Xenon Pharmaceuticals Profile
Xenon Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company’s products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J.
Read More
- Get a free copy of the StockNews.com research report on Xenon Pharmaceuticals (XENE)
- Apple Crushes; Get Ready For All-Time Highs
- Investors Are Barking Up The Right Tree With Datadog
- How to Invest in Central Bank Digital Currency
- Kellogg Company Looks GRRR-eat! At These Levels
- PacWest, First Horizon Shares Plummet On Continued Bank Worries
Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating).
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
